Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00910247 · ClinicalTrials.gov registry record · Phase 3
Eslicarbazepine Acetate Monotherapy Long Term Study
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 274
- Enrollment target
NCT00910247: Completed Phase 3 study, sponsored by Sumitomo Pharma America.
NCT00910247 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 274 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00910247, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 274 participants
- Enrollment target
Study Summary
This is a long term, open-label, safety extension study in subjects with partial onset seizures.
Primary Outcome
Number and percent of subjects with treatment emergent adverse events
Interventions
- DRUG Eslicarbazepine acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2009-08 |
| Est. Completion | 2017-04-15 |
| Phase | Phase 3 |
What the finished NCT00910247 record still lists
NCT00910247 is an interventional study that assigns participants to a tested intervention. The registered 274 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 1 intervention - of which Eslicarbazepine acetate is the first listed.
NCT00910247 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00910247 about?
NCT00910247 is a clinical study titled "Eslicarbazepine Acetate Monotherapy Long Term Study". This is a long term, open-label, safety extension study in subjects with partial onset seizures.
What is the current status of trial NCT00910247?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 274 participants. The study started on 2009-08. Estimated completion is 2017-04-15.
What interventions are being tested in trial NCT00910247?
The interventions under investigation include: Eslicarbazepine acetate (DRUG).
Who is sponsoring clinical trial NCT00910247?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00910247's enrollment target sits among peer trials
274 1207th of 2000 higher than 788 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03808922 · 274 participants · Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- NCT04573504 · 274 participants · Phase 4
Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair
- NCT05289557 · 274 participants · Phase 3
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
- NCT05952583 · 274 participants
Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia